세계의 당뇨병성 족부 궤양 치료 시장 예측(-2030년) : 치료 유형, 궤양 유형, 최종 사용자 및 지역별 분석

According to Stratistics MRC, the Global Diabetic Foot Ulcer Treatment Market is accounted for $9.02 billion in 2024 and is expected to reach $14.55 billion by 2030 growing at a CAGR of 8.3% during the forecast period. Diabetic foot ulcer treatment encompasses a range of medical and therapeutic interventions aimed at healing ulcers resulting from diabetes-related complications. These treatments include wound care management, such as debridement and the application of advanced dressings, as well as the use of antimicrobial agents to prevent infection. In severe cases, surgical interventions may be necessary. Additionally, patient education on proper foot care and diabetes management plays a vital role in preventing ulcer recurrence. The ultimate goal is to promote healing, reduce complications, and enhance the quality of life for affected individuals.

Market Dynamics:

Driver:

Rising Diabetes Prevalence

Rising diabetes prevalence significantly impacts the market by increasing the number of patients at risk for foot complications. As diabetes cases grow, more individuals experience neuropathy and poor circulation, leading to a higher incidence of foot ulcers. This trend drives demand for advanced treatment options, including specialized wound care products and therapies. Additionally, healthcare systems are compelled to implement comprehensive management strategies to address these challenges, further fueling market growth.

Restraint:

High Treatment Costs

High treatment costs significantly impact the market by limiting access to advanced therapies for many patients. The expense associated with specialized wound care products and technologies can discourage timely intervention, leading to increased complications and worsening conditions. This financial barrier may result in delayed treatment, ultimately affecting patient outcomes. Thus, it hinders the growth opf the market.

Opportunity:

Advancements in Technology

Advancements in technology are transforming the market by introducing innovative wound care solutions, such as smart dressings, bioactive materials, and telehealth services. These technologies enhance the effectiveness of treatment, promote faster healing, and allow for better patient monitoring. The integration of data analytics and mobile health applications facilitates personalized care, improving outcomes and patient engagement. As healthcare providers increasingly adopt these technologies, the demand for advanced diabetic foot ulcer treatments grows, thus it drives the growth of the market.

Threat:

Limited Healthcare Access

Limited healthcare access impacts the market by hindering timely diagnosis and intervention for patients. In underserved regions, a lack of medical facilities and specialized care can result in delayed treatments, increasing the risk of complications like infections and amputations. This scenario leads to poorer patient outcomes and higher long-term healthcare costs, emphasizing the need for improved healthcare infrastructure and accessibility to ensure effective management of diabetic foot ulcers, thus it hampers the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic adversely affected the diabetic foot ulcer treatment market by causing delays in elective procedures and reducing patient visits to healthcare facilities due to lockdowns. This leads to increased complications and worsening conditions among diabetic patients. However, the crisis also spurred innovation in telehealth and remote monitoring, improving access to care.

The neuropathic ulcers segment is expected to be the largest during the forecast period

The neuropathic ulcers segment is expected to be the largest during the forecast period as these ulcers often result from nerve damage, leading to reduced sensation and unrecognized injuries. The growing prevalence of neuropathic ulcers drives demand for specialized treatments and advanced care solutions. As healthcare providers focus on comprehensive management strategies, including regular screening and tailored therapies, the market for diabetic foot ulcer treatments continues to expand, emphasizing the importance of addressing neuropathic conditions in patient care.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period because Increased focus on multidisciplinary approaches, including podiatry, wound care, and diabetes management, enhances patient outcomes. Hospitals are also instrumental in raising awareness about the importance of early intervention and preventative care. Moreover, their investment in advanced technologies and wound care products drives innovation in the market, improving accessibility and efficiency in treating diabetic foot ulcers across the healthcare system.

Region with largest share:

North America is projected to hold the largest market share during the forecast period as it addresses the rising incidence of diabetes and its complications. Innovative therapies and advanced wound care technologies improve patient management, reducing the risk of infections and amputations. This market's growth enhances access to effective treatments, ultimately leading to better patient quality of life. Increased awareness among healthcare providers further emphasizes the importance of preventative care and timely intervention, fostering a comprehensive approach to managing diabetic foot ulcers in the region.

Region with highest CAGR:

Asia Pacific is projected to witness the highest CAGR over the forecast period owing to rising prevalence of diabetes and related complications. Increasing awareness of proper foot care and advancements in treatment technologies are driving demand for effective therapies. Additionally, government initiatives aimed at improving diabetes management and healthcare infrastructure are enhancing access to treatments. This growth is further supported by the expanding aging population and the increasing incidence of obesity.

Key players in the market

Some of the key players in Diabetic Foot Ulcer Treatment Market include 3M Healthcare, Acelity L.P. Inc. (KCI), Advanced Tissue, Alliqua Biomedical, Inc., B. Braun Melsungen AG, BSN Medical GmbH, Cardinal Health, Inc., Coloplast A/S, ConvaTec Group Plc, Derma Sciences Inc., Hollister Incorporated, Integra LifeSciences Corporation, Medline Industries, Inc., Medtronic Plc, Molnlycke Health Care AB, Organogenesis Inc., Osiris Therapeutics, Inc., Paul Hartmann AG, Smith & Nephew Plc and Wound Care Innovations, LLC.

Key Developments:

In August 2024, Cardinal Health expanded medical product distribution footprint in Northeast Ohio, to support its U.S. Medical Products and Distribution business.

In November 2023, Cardinal Health announced the U.S. launch of its SmartGown EDGE Breathable Surgical Gown with ASSIST Instrument Pockets, created to provide surgical teams safe and convenient instrument access in the operating room.

In September 2023, Cardinal Health announced the U.S. launch of its Kangaroo OMNI Enteral Feeding Pump, designed to help provide enteral feeding patients with more options to meet their personalized needs throughout their enteral feeding journey.

Treatment Types Covered:

• Wound Care Dressings
• Wound Care Devices
• Biologics
• Antibiotics
• Surgical Procedures

Ulcer Types Covered:

• Neuropathic Ulcers
• Ischemic Ulcers
• Neuroischemic Ulcers

End Users Covered:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Diabetic Foot Ulcer Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 Wound Care Dressings
  • 5.2.1 Foam Dressings
  • 5.2.2 Hydrocolloid Dressings
  • 5.2.3 Alginate Dressings
  • 5.2.4 Hydrogel Dressings
  • 5.2.5 Other Advanced Dressings
• 5.3 Wound Care Devices
  • 5.3.1 Negative Pressure Wound Therapy (NPWT)
  • 5.3.2 Ultrasound Therapy Devices
  • 5.3.3 Hyperbaric Oxygen Therapy (HBOT)
  • 5.3.4 Electrical Stimulation Devices
• 5.4 Biologics
  • 5.4.1 Skin Substitutes
  • 5.4.2 Tissue-Engineered Products
• 5.5 Antibiotics
  • 5.5.1 Topical Antibiotics
  • 5.5.2 Oral Antibiotics
• 5.6 Surgical Procedures
  • 5.6.1 Debridement
  • 5.6.2 Revascularization
  • 5.6.3 Skin Grafting

6 Global Diabetic Foot Ulcer Treatment Market, By Ulcer Type

• 6.1 Introduction
• 6.2 Neuropathic Ulcers
• 6.3 Ischemic Ulcers
• 6.4 Neuroischemic Ulcers

7 Global Diabetic Foot Ulcer Treatment Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Specialty Clinics
• 7.4 Ambulatory Surgical Centers
• 7.5 Home Care Settings
• 7.6 Other End Users

8 Global Diabetic Foot Ulcer Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 3M Healthcare
• 10.2 Acelity L.P. Inc. (KCI)
• 10.3 Advanced Tissue
• 10.4 Alliqua Biomedical, Inc.
• 10.5 B. Braun Melsungen AG
• 10.6 BSN Medical GmbH
• 10.7 Cardinal Health, Inc.
• 10.8 Coloplast A/S
• 10.9 ConvaTec Group Plc
• 10.10 Derma Sciences Inc.
• 10.11 Hollister Incorporated
• 10.12 Integra LifeSciences Corporation
• 10.13 Medline Industries, Inc.
• 10.14 Medtronic Plc
• 10.15 Molnlycke Health Care AB
• 10.16 Organogenesis Inc.
• 10.17 Osiris Therapeutics, Inc.
• 10.18 Paul Hartmann AG
• 10.19 Smith & Nephew Plc
• 10.20 Wound Care Innovations, LLC